跳至主要内容
临床试验/CTRI/2019/08/020762
CTRI/2019/08/020762已完成2 期

Microbial origin mitochondria-targeted nutraceutical therapy in progressive respiratory diseases

CSIR0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
CSIR
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • •Patients with a clinical and / or radiological diagnosis of COPD and ILD in the Pulmonary medicine OPD and clinics.
  • •Definition of COPD: (a common preventable and treatable disease characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients). Classification of severity will be done based on GOLD 2018 criteria using spirometry according to ATS / ERS recommendations (2005).
  • •Definition of ILD: (patients with diagnosis of ILD based on clinical features, spirometry and radiological (HRCT chest) basis. All types of ILD will be included. Adult subjects

排除标准

  • •1. Patients other diseases such as lung cancer or pulmonary tuberculosis will be excluded from this study.
  • •2. Pregnant women will be excluded from this study.
  • •3. Patients not willing to give consent will be excluded.

研究者

发起方
CSIR

相似试验

Mitochondria-targeted Pyrroloquinoline quinone... | 临床试验